
YORK, Penn., Nov. 06, 2026 (GLOBE NEWSWIRE) -- The York Water Company's (NASDAQ:YORW) President, JT Hand, announced the Company's financial results for the third quarter and the first nine months of 2026. President Hand reported that third quarter operating revenues of $24,333,000 increased $3,972,000, and net income of $7,809,000 increased $1,608,000 compared to the third quarter of 2025. Basic and Diluted Earnings per share of $0.48 for the three-month period increased $0.05 compared to the sa
Earnings Release: Thursday, November 12, 2026, Before Market Open in New York GLYFADA, Greece, Nov. 06, 2026 (GLOBE NEWSWIRE) -- United Maritime Corporation (the “Company” or “United”) (NASDAQ: USEA), announced today that it will release its financial results for the third quarter and nine months ended September 30, 2026, prior to the open of the market in New York on Thursday, November 12, 2026. About United Maritime Corporation United Maritime Corporation is an international shipping company s
newsConfirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic science beyond dopaminergic mechanisms and to improve clinical trial methodology for negative symptoms Roluperidone remains the only late-stage drug candidate for this high-need population Company to host in-person and virtual KOL event on November 12, 2026 at 10:00 AM ET BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE)

Earnings Release: Thursday, November 12, 2026, Before Market Open in New York GLYFADA, Greece, Nov. 06, 2026 (GLOBE NEWSWIRE) -- United Maritime Corporation (the “Company” or “United”) (NASDAQ: USEA), announced today that it will release its financial results for the third quarter and nine months ended September 30, 2026, prior to the open of the market in New York on Thursday, November 12, 2026. About United Maritime Corporation United Maritime Corporation is an international shipping company s
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic science beyond dopaminergic mechanisms and to improve clinical trial methodology for negative symptoms Roluperidone remains the only late-stage drug candidate for this high-need population Company to host in-person and virtual KOL event on November 12, 2026 at 10:00 AM ET BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE)
newsKIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma completed target enrollment of 540 patients – Topline overall survival data expected second quarter of 2027 Promising Phase 1 data with KIMMTRAK plus brenetafusp to be presented as a late-breaking oral at SITC - Randomized Phase 2/3

Earnings Release: Thursday, November 12, 2026, Before Market Open in New York GLYFADA, Greece, Nov. 06, 2026 (GLOBE NEWSWIRE) -- United Maritime Corporation (the “Company” or “United”) (NASDAQ: USEA), announced today that it will release its financial results for the third quarter and nine months ended September 30, 2026, prior to the open of the market in New York on Thursday, November 12, 2026. About United Maritime Corporation United Maritime Corporation is an international shipping company s
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic science beyond dopaminergic mechanisms and to improve clinical trial methodology for negative symptoms Roluperidone remains the only late-stage drug candidate for this high-need population Company to host in-person and virtual KOL event on November 12, 2026 at 10:00 AM ET BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE)
newsKIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma completed target enrollment of 540 patients – Topline overall survival data expected second quarter of 2027 Promising Phase 1 data with KIMMTRAK plus brenetafusp to be presented as a late-breaking oral at SITC - Randomized Phase 2/3

YORK, Penn., Nov. 06, 2026 (GLOBE NEWSWIRE) -- The York Water Company's (NASDAQ:YORW) President, JT Hand, announced the Company's financial results for the third quarter and the first nine months of 2026. President Hand reported that third quarter operating revenues of $24,333,000 increased $3,972,000, and net income of $7,809,000 increased $1,608,000 compared to the third quarter of 2025. Basic and Diluted Earnings per share of $0.48 for the three-month period increased $0.05 compared to the sa
The Ozempic market is projected to register a CAGR of 24.89% during 2027–2032, supported by expanding diabetes treatment demand, broader metabolic health applications, and growing adoption of GLP-1 therapies. Hyderabad, India, Nov. 06, 2026 (GLOBE NEWSWIRE) -- The Ozempic market size was valued at USD 30.04 billion in 2026 and is estimated to grow from USD 37.51 billion in 2027 to reach USD 113.95 billion by 2032 , at a CAGR of 24.89% during the forecast period (2027–2032) . The market is gainin
newsKIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma completed target enrollment of 540 patients – Topline overall survival data expected second quarter of 2027 Promising Phase 1 data with KIMMTRAK plus brenetafusp to be presented as a late-breaking oral at SITC - Randomized Phase 2/3

Earnings Release: Thursday, November 12, 2026, Before Market Open in New York GLYFADA, Greece, Nov. 06, 2026 (GLOBE NEWSWIRE) -- United Maritime Corporation (the “Company” or “United”) (NASDAQ: USEA), announced today that it will release its financial results for the third quarter and nine months ended September 30, 2026, prior to the open of the market in New York on Thursday, November 12, 2026. About United Maritime Corporation United Maritime Corporation is an international shipping company s
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic science beyond dopaminergic mechanisms and to improve clinical trial methodology for negative symptoms Roluperidone remains the only late-stage drug candidate for this high-need population Company to host in-person and virtual KOL event on November 12, 2026 at 10:00 AM ET BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE)
newsKIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma completed target enrollment of 540 patients – Topline overall survival data expected second quarter of 2027 Promising Phase 1 data with KIMMTRAK plus brenetafusp to be presented as a late-breaking oral at SITC - Randomized Phase 2/3
Growth is being redefined. Expanding revenue remains important, but businesses are placing greater emphasis on profitability, cash discipline, operational efficiency, customer retention and resilience. This edition explores the changing growth playbook and the foundations required for sustainable expansion. From technology and process design to capital allocation and market reach, it examines how businesses can pursue ambition without allowing complexity, costs or uncontrolled expansion to weaken the enterprise.
For years, growth was often discussed primarily in terms of size, speed and market share. The conversation is becoming more balanced. Strong businesses also need healthy economics, efficient operations and the ability to withstand uncertainty. This edition looks at growth through that wider lens and considers how organizations can expand with greater discipline, clarity and long-term purpose in practice.
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.